Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDC folic acid grant

This article was originally published in The Tan Sheet

Executive Summary

Roughly $200,000 is available in FY 2002 funds for a prevention recurrence program for neural tube defects to increase "maternal preconceptional and periconceptional use of folic acid supplementation," according to June 12 Federal Register notice. Applicants must be "well-established national, nonprofit organizations" with health education experience, CDC notes. Applications are due July 10; funds will be available Sept. 1. Separately, March of Dimes reports "almost 70 % of American women of childbearing age fail to take the B vitamin folic acid every day." Gallup phone survey of 2,004 women ages 18-45 reveals only 31% of women take multivitamin with folic acid, up slightly from 1995...

You may also be interested in...

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

FDA Guides On Virtual Inspections During COVID-19

Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts